Pure Global AI
NCT05996445Recruiting

A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®662 in Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
Xencor, Inc.Phase 1ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Solid Tumors
Drug/Device/Intervention
XmAb662
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Xencor, Inc.
Location
Charlottesville, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Jul 28, 2023
End date
Sep 30, 2030
Enrollment
210 participants
Primary outcome

Incidence of dose-limiting toxicities (DLTs),Incidence and severity of treatment emergent adverse events (TEAEs)

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
 intravenous administration of XmAb662 monotherapy or in combination with pembrolizumab in
 subjects with advanced solid tumors and to identify the recommended dose regimen that is safe
 and biologically effective for XmAb662.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm of other connective and soft tissueCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Parametrium
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05996445
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05996445 through Pure Global AI's free database. This Phase 1 trial is sponsored by Xencor, Inc. and is currently Recruiting. The study focuses on Solid Tumors. Target enrollment is 210 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.